肝细胞癌相关蛋白TD26与固醇调节元件结合蛋白1相互作用并增强其活性以促进肿瘤细胞增殖与生长
肝细胞癌中脂质合成增加机制未明。研究发现TD26在肝癌组织高表达,与肿瘤大小正相关,是总生存和无复发生存的独立预测因子;TD26通过C末端与nSREBP1结合,阻断AMPK对SREBP1活性的抑制,促进脂质合成和肿瘤生长。
要点
- TD26在肝癌组织高表达,与肿瘤大小正相关,是OS和RFS的独立预测因子。
- TD26不影响糖代谢,但显著增加肝癌细胞脂质合成,促进增殖和肿瘤生长。
- TD26通过C末端(aa 121-198)与nSREBP1结合,阻断AMPK对SREBP1的抑制。
核心结论
- TD26是SREBP1转录活性的正调控因子,TD26与SREBP1的相互作用可作为肝癌治疗的潜在靶点。
研究设计与样本
- 研究比较肝癌组织与配对正常组织的TD26表达,对两个独立肝癌队列进行临床病理分析,并开展代谢组学与功能实验。
主要发现
- TD26在肝癌肿瘤组织中高表达于配对正常组织。
- 两个独立肝癌队列分析显示TD26表达与肿瘤大小正相关,是总生存和无复发生存的独立预测因子。
- 代谢组学显示TD26对糖代谢无影响,但显著增加肝癌细胞脂质合成。
- 功能实验显示TD26促进肝癌细胞增殖和肿瘤生长,该作用依赖SREBP1。
- TD26通过C末端(氨基酸121至198)与截短核型SREBP1结合而非全长SREBP1,阻断AMPK介导的对SREBP1活性的抑制。
临床怎么用
- 原文结论提出TD26与SREBP1的相互作用可作为肝癌治疗的潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Increased lipogenesis has been reported to play a critical role in HCC progression. However, the underlying mechanism contributing to lipogenesis increase in HCC remains elusive. Here, we show that HCC-associated protein TD26 (TD26) was highly expressed in HCC tumor tissues compared to matched normal tissues. From the clinicopathologic analyses of two independent HCC cohorts, we demonstrate that TD26 expression was positively correlated with tumor size and was an independent predictor of overall survival (OS) and recurrence-free survival (RFS) in HCC patients. Our metabolomics assays demonstrate that TD26 had no effect on glycometabolism, but significantly increased lipogenesis in HCC cells. In addition, our functional assays indicate that TD26 promoted HCC cell proliferation and tumor growth. We further demonstrate that TD26-mediated increase in lipogenesis and tumor cell proliferation was SREBP1 dependent. Mechanistically, we demonstrate that, through its C-terminus (amino acids [aa] from 121 to 198), TD26 interacted with the truncated nuclear sterol regulatory element-binding protein 1 (SREBP1) form (nSREBP1), but not full-length SREBP1 (flSREBP1), to block adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)-mediated inhibition on SREBP1 activity, resulting in increased lipogenesis, elevated tumor cell proliferation, and enhanced tumor progression. Conclusion: We propose that TD26 is a positive regulator on SREBP1 transactivity, and the interaction between TD26 and SREBP1 can serve as a potential therapeutic target for HCC treatment.
引用
- Wang C, Tong Y, Wen Y, et al. Hepatocellular Carcinoma-Associated Protein TD26 Interacts and Enhances Sterol Regulatory Element-Binding Protein 1 Activity to Promote Tumor Cell Proliferation and Growth. Hepatology. 2018. PMID: 29663480. doi:10.1002/hep.30030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。